Lyme Disease Testing: Types, Accuracy, and When to Get Tested
Explore the clinic directoryIn this article
Key Takeaways
- The CDC two-tier protocol (ELISA followed by Western blot) detects only about 29% to 40% of early localized Lyme disease, so it misses roughly 60% to 70% of early cases.
- Antibodies take 2 to 6 weeks to develop after a tick bite, which is why the IDSA, AAN and ACR (2020) recommend against testing people with no symptoms right after a bite.
- Since July 2019 the FDA has cleared modified two-tier tests that use a second EIA instead of a Western blot, and the CDC accepts them as an alternative (Mead and colleagues, 2019).
- PCR detects Borrelia DNA directly and works best on joint fluid, where the 2020 guideline reports sensitivity of 71% to 100% in untreated Lyme arthritis, compared with mostly 30% to 50% in blood.
- Specialty labs such as iGeneX use expanded panels that may catch cases standard labs miss, but the IDSA guideline advises against unvalidated methods such as urine antigen and CD57 tests.
- Lyme disease is a clinical diagnosis supported by testing: symptoms, tick exposure and the exam matter as much as the lab report, especially in early Lyme.
Lyme disease testing in the United States is a two-step blood test: a screening ELISA (enzyme immunoassay) and, if that is positive or equivocal, a Western blot or second EIA that confirms antibodies to Borrelia burgdorferi. Because antibodies take 2 to 6 weeks to form, this two-tier test detects only about 29% to 40% of early Lyme disease, so the 2020 IDSA, AAN and ACR guideline says a typical erythema migrans rash is diagnosed clinically, without a test.
If you suspect Lyme disease, getting the right test at the right time can mean the difference between a quick recovery and months (or years) of unexplained symptoms. The problem? Lyme testing is far from perfect. The standard tests miss a significant number of cases, and the timing of when you test matters enormously.
The sections below cover every major Lyme disease test available today, from the ELISA and Western blot to PCR, modified two-tier testing and specialty lab panels. Each one explains what the results actually mean and when standard testing falls short. If you are still learning about the illness itself, the Lyme disease condition overview covers symptoms, stages and how it spreads.
How the Standard Two-Tier Testing Protocol Works
The CDC recommends a two-step process for diagnosing Lyme disease. First, your doctor orders an ELISA (enzyme-linked immunosorbent assay) test. If that comes back positive or equivocal, a Western Blot test is run to confirm the result.
The logic sounds reasonable: use a sensitive screening test first, then confirm with a more specific test. In practice, this system has serious gaps that every patient should understand.
Step 1: The ELISA Test
The ELISA measures antibodies your immune system produces in response to Borrelia burgdorferi, the bacterium that causes Lyme disease. A blood sample is mixed with Lyme antigens. If your blood contains antibodies against Borrelia, they bind to these antigens and produce a measurable color change.
The ELISA is designed to be highly sensitive, meaning it should catch most true positives. The trade-off is that it also produces false positives from cross-reactivity with other infections (EBV, syphilis, autoimmune conditions). That is why a positive ELISA alone is not considered diagnostic.
Step 2: The Western Blot
If your ELISA is positive or borderline, the Western Blot test separates Borrelia proteins by size and checks which specific antibody “bands” your immune system reacts to. The CDC requires reactivity to a set number of bands for a positive result:
- IgM Western Blot: At least 2 of 3 specific bands (23, 39, 41 kDa) within the first 30 days of infection
- IgG Western Blot: At least 5 of 10 specific bands for infections lasting longer than 30 days
This strict band requirement is where many patients fall through the cracks. You might react to 4 out of 10 IgG bands, all highly specific to Borrelia, and still receive a “negative” result by CDC standards.
The Modified Two-Tier Test (MTTT)
On July 29, 2019, the FDA cleared several Lyme assays for a modified two-tier test, which runs a second EIA in place of the Western blot. According to Mead, Petersen and Hinckley in the CDC’s MMWR (2019), FDA-cleared modified two-tier assays are acceptable alternatives to the standard protocol.
Western Blot vs ELISA: Which Lyme Test Is More Accurate?
Neither test is accurate on its own, which is why they are run in sequence. The ELISA is the more sensitive test and is built to flag almost everyone who might have antibodies, at the cost of false positives. The Western blot is the more specific test and is built to confirm that the antibodies are truly directed at Borrelia, at the cost of missing borderline and early cases.
Accuracy also depends heavily on timing. In the 2020 IDSA, AAN and ACR guideline, as few as 20% of patients with confirmed erythema migrans were positive on two-tier testing within a week of noticing the rash, and one comparison study found 40.4% sensitivity in the acute phase. By the time Lyme arthritis or neurologic Lyme develops, the combined test detects most cases.
| Attribute | ELISA (EIA) | Western blot (immunoblot) |
|---|---|---|
| Role in testing | First tier, screening | Second tier, confirmation |
| What it reads | Overall antibody level against Borrelia antigens | Reactivity to individual Borrelia protein bands |
| Main strength | High sensitivity once antibodies exist | High specificity for Borrelia |
| Main weakness | Cross-reacts with EBV, syphilis and autoimmune disease | Strict band counts miss borderline results |
| Used alone? | No, a positive needs confirmation | No, only after a positive or equivocal ELISA |
The False Negative Problem
This is the single biggest issue with Lyme testing, and it trips up both patients and doctors. Multiple studies show that the two-tier protocol has a sensitivity of only 29% to 40% in early localized Lyme disease. That means it misses 60% to 70% of people who actually have early Lyme.
Why False Negatives Happen
- Testing too early. Your immune system needs 2 to 6 weeks to produce detectable antibodies. Testing during the first week or two after a bite will almost always come back negative, even if you are infected.
- Antibiotic use. If you start antibiotics early (which is the right clinical decision), they can blunt your immune response and reduce antibody production, leading to a negative test.
- Immune suppression. Patients with weakened immune systems may not produce enough antibodies to trigger a positive result.
- Borrelia strain variation. The standard tests are optimized for B. burgdorferi sensu stricto. Other pathogenic Borrelia species may not trigger the same antibody patterns.
Sensitivity improves significantly in later-stage Lyme disease, reaching 70% to 100% for patients with Lyme arthritis or neurological Lyme. But by that point, the infection has had weeks or months to cause damage that earlier treatment could have prevented.
A negative result early in the illness is a reason to retest, not a final answer. The 2020 guideline from the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN) and American College of Rheumatology (ACR) suggests an acute blood sample followed by a convalescent sample a few weeks later when an early rash is atypical and the first result is negative. A rise from negative to positive between the two draws is strong evidence of recent infection.
PCR Testing: Detecting Borrelia DNA Directly
Unlike antibody-based tests, PCR (polymerase chain reaction) testing looks for Borrelia DNA itself. This is a direct detection method. If Borrelia genetic material is present in your sample, PCR can amplify it to detectable levels.
PCR has a major advantage: it does not depend on your immune response. You do not need to wait weeks for antibodies to build up. It can also identify the specific Borrelia species involved.
The downside is that Borrelia spirochetes do not circulate freely in blood for very long. They burrow into tissues quickly. This means PCR testing on blood samples has low sensitivity (often below 30%). Where PCR shines is in testing synovial (joint) fluid from patients with Lyme arthritis, where sensitivity can exceed 70%, and in cerebrospinal fluid for neurological Lyme.
The published ranges vary by sample type. According to the IDSA, AAN and ACR guideline by Lantos and colleagues (2021), blood PCR sensitivity in US studies falls mostly between 30% and 50%, synovial fluid PCR reaches 71% to 100% in untreated Lyme arthritis, and cerebrospinal fluid PCR is often low, around 17% in one meta-analysis. For that reason the guideline still prefers serum antibody testing for suspected neuroborreliosis, and uses joint fluid PCR to add certainty in people who are already seropositive.
Specialty Labs and Expanded Testing
Several laboratories offer testing panels that go beyond the standard two-tier approach. These labs have become particularly important for patients whose clinical picture strongly suggests Lyme but whose standard tests come back negative.
iGeneX
iGeneX in Milpitas, California, is the most well-known specialty Lyme lab. Their ImmunoBlot test uses more Borrelia antigens than standard Western Blot panels, including antigens from multiple Borrelia species. They also report “indeterminate” bands that standard labs ignore entirely.
iGeneX testing has drawn criticism from some infectious disease specialists who argue it produces too many false positives. Proponents counter that it simply catches cases the standard protocol misses. The reality likely falls somewhere in between: iGeneX testing is more sensitive but potentially less specific. It should be interpreted in clinical context, not used as a standalone diagnostic.
Other Specialty Testing Options
Vibrant Wellness Tickborne Panel: Tests for multiple tick-borne infections simultaneously and includes both antibody and antigen detection.
Galaxy Diagnostics: Specializes in Bartonella testing but also offers Borrelia panels using enrichment culture methods.
ArminLabs (Germany): Offers EliSpot testing, which measures T-cell responses to Borrelia, and CD57 counts, a marker on natural killer cells, providing a different angle than antibody-only tests.
What the Evidence Says About Specialty Panels
The evidence for most specialty methods is thin. The 2020 IDSA, AAN and ACR guideline advises clinicians to avoid nonstandard serology interpretation, urine antigen tests, the lymphocyte transformation test and quantitative CD57 assays, citing a lack of systematic, independent and reproducible validation studies. ILADS clinicians tend to give these results more weight when symptoms and exposure fit.
Specialty panels are usually cash pay and are often not covered by insurance. If you use one, ask the ordering clinician which criteria the lab applies, whether the method is FDA cleared or a laboratory developed test, and how a positive or negative result would change treatment.
Comparing Lyme Disease Tests
| Test | What It Measures | Best Timing | Sensitivity (Early/Late) | Key Limitation |
|---|---|---|---|---|
| ELISA | Total antibodies to Borrelia | 4+ weeks post-bite | 40-70% / 90-100% | High false negative rate early; cross-reactivity |
| Western Blot (IgM) | Specific antibody bands | 2-4 weeks post-bite | 30-40% / Not used after 30 days | Strict band criteria miss borderline cases |
| Western Blot (IgG) | Specific antibody bands | 6+ weeks post-bite | Low / 70-100% | Takes weeks to turn positive |
| PCR (blood) | Borrelia DNA | First 2 weeks | Under 30% / Under 30% | Spirochetes leave blood quickly |
| PCR (joint fluid) | Borrelia DNA | During active arthritis | N/A / 60-80% | Requires joint aspiration |
| iGeneX ImmunoBlot | Expanded antibody panel | 4+ weeks post-bite | Higher than standard / High | May overcall some positives |
| EliSpot (T-cell) | T-cell reactivity | Any time | Variable / Variable | Not widely validated in the US |
When Should You Get Tested?
The timing of your test depends on your situation:
You found a tick and removed it. Do not rush to get tested the next day. Antibody tests will almost certainly be negative. Wait at least 2 to 3 weeks before testing. If you develop a rash (especially an expanding bull’s-eye rash), your doctor should treat you clinically without waiting for test results. The rash alone is diagnostic.
You have a bull’s-eye (erythema migrans) rash. No testing needed. This rash is considered diagnostic of Lyme disease. Treatment should begin immediately. Testing at this stage often produces false negatives and can delay treatment that should already be underway.
You have unexplained symptoms weeks after possible tick exposure. This is the ideal window for two-tier testing. Antibodies should be detectable by 4 to 6 weeks post-infection. Symptoms like fatigue, joint pain, headaches, and cognitive fog in someone who lives in or has visited a Lyme-endemic area should prompt testing.
You have chronic unexplained symptoms. If you have been dealing with fatigue, pain, neurological symptoms, or other issues for months or years, and no other diagnosis explains them, Lyme testing is reasonable. Consider specialty lab testing if standard tests are negative but clinical suspicion remains high.
Is 4 Weeks After a Tick Bite Long Enough to Test?
Four weeks after a bite is a reasonable time to test if you have symptoms, because most infected people have measurable IgM antibodies by then and IgG is starting to appear. A negative result at 4 weeks is not final: if symptoms continue, a repeat test at 6 to 8 weeks catches many people who were still building antibodies. Without symptoms, the 2020 IDSA, AAN and ACR guideline recommends against testing at all after a tick bite.
What About Preventive Antibiotics After a Bite?
Testing and prevention are separate decisions. For a high-risk bite from an Ixodes (blacklegged or deer) tick, the 2020 guideline recommends a single oral dose of doxycycline, 200 mg for adults and 4.4 mg/kg up to 200 mg for children, taken within 72 hours of removing the tick. A clinician decides whether a bite counts as high risk based on the tick, how long it was attached and local Lyme rates.
How to Test for Lyme Disease, Step by Step
Testing for Lyme disease follows the same order in most US practices, whether you start with a primary care physician, an urgent care clinic or a specialist.
- Note your exposure. Write down the date of any tick bite, where you were, and when each symptom started. Lyme risk is highest in the Northeast, the mid-Atlantic and the upper Midwest.
- Photograph any rash. An expanding erythema migrans rash is enough for a clinical diagnosis, and a dated photo helps if the rash fades before your visit.
- Ask for two-tier serology at the right time. Your clinician orders an ELISA or EIA, followed by a Western blot or a second EIA if the first result is positive or equivocal.
- Repeat if the first test was early. A convalescent sample 2 to 4 weeks later can turn positive when the first one was drawn too soon.
- Add targeted tests for specific symptoms. Joint swelling may lead to joint fluid PCR, facial palsy or meningitis may lead to cerebrospinal fluid testing, and palpitations or fainting may lead to an ECG for Lyme carditis.
- Ask about co-infections. The same ticks can carry Babesia microti, Anaplasma phagocytophilum and Borrelia miyamotoi, which need their own tests.
More detail on those other infections is in the guide to Lyme disease co-infections.
Understanding Your Test Results
Test results can be confusing, especially when different labs report them differently. Here is what the common scenarios mean:
ELISA negative: By CDC protocol, testing stops here. No Western Blot is performed. This does not rule out Lyme, especially if tested early or if you are immunocompromised.
ELISA positive, Western Blot negative: Officially negative for Lyme by two-tier criteria. This could represent a false positive ELISA (from cross-reactivity) or a false negative Western Blot (antibodies present but not meeting the strict band count). Clinical judgment is needed.
ELISA positive, Western Blot positive: Confirms Lyme disease exposure. Note that antibodies can persist for months or years after successful treatment, so a positive test does not necessarily mean active infection in someone who has been previously treated.
IgM positive only (beyond 30 days): The CDC considers IgM results unreliable after 30 days of illness because false positives increase over time. However, some Lyme-literate physicians interpret a positive IgM differently, particularly if specific bands like the 23 kDa (OspC) and 39 kDa bands are reactive.
The Role of Clinical Diagnosis
Given the limitations of current testing, Lyme disease should never be diagnosed or ruled out by blood work alone. A skilled clinician considers:
- Your symptom pattern and timeline
- Tick exposure history and geographic risk
- Physical exam findings
- Response to treatment (sometimes a trial of antibiotics is both diagnostic and therapeutic)
- Laboratory results as one piece of a larger puzzle
The International Lyme and Associated Diseases Society (ILADS) emphasizes that Lyme disease is a clinical diagnosis supported by testing, not a test-dependent diagnosis. This is especially true in early Lyme, where treatment should not be delayed while waiting for antibodies to develop.
Who Orders and Interprets Lyme Disease Tests?
Primary care physicians, pediatricians and urgent care clinicians order most first Lyme tests. Infectious disease specialists handle unclear or late cases, rheumatologists see Lyme arthritis, neurologists see facial palsy and neuroborreliosis, and cardiologists see Lyme carditis. Functional and integrative medicine clinicians, including physicians who describe themselves as Lyme literate and often follow ILADS guidance, are more likely to order specialty panels.
If testing confirms Lyme, or symptoms continue after standard antibiotics, the Lyme disease treatment guide covers the treatment options patients ask about and where the evidence for each is limited. To compare practitioners, you can browse Lyme disease treatment clinics across the US. Regenerated.com is free for patients, listing order is not paid ranking, Featured slots are labeled and capped, and Verified means credential checks, not spend. Inclusion in the directory is not an endorsement.
Newer Testing Approaches on the Horizon
Researchers are working on several next-generation tests that may eventually replace the two-tier protocol:
- Modified two-tier testing (MTTT): Uses two ELISA tests instead of ELISA plus Western Blot. Early studies suggest improved sensitivity in early Lyme without sacrificing specificity.
- Metabolomics-based tests: Analyze patterns of metabolites in blood that change during Borrelia infection. Could potentially detect infection before antibodies appear.
- Direct antigen detection: New technologies aim to detect Borrelia proteins (like OspA) shed into blood or urine, bypassing the need for an immune response entirely.
- T-cell based assays: Measure cellular immune responses rather than antibodies, potentially offering a more accurate picture of active infection.
Of these, only the modified two-tier approach has moved into routine use. The FDA cleared the first modified two-tier assays on July 29, 2019, the CDC accepted them as an alternative the same year, and some labs have already adopted them. The others remain research tools, and none has FDA clearance for diagnosing Lyme disease.
Frequently Asked Questions About Lyme Disease Testing
How do you test for Lyme disease?
Lyme disease is tested with a blood draw for two-tier serology. A lab first runs an ELISA or EIA to screen for antibodies to Borrelia burgdorferi, then confirms a positive or equivocal result with a Western blot or a second EIA. A clinician reads the result alongside your symptoms and tick exposure. An erythema migrans rash in an endemic area is diagnosed without any test, according to the 2020 IDSA, AAN and ACR guideline.
How soon after a tick bite can you test for Lyme disease?
Antibody tests become reliable about 4 to 6 weeks after infection, because the immune system needs 2 to 6 weeks to make detectable antibodies. Testing in the first week or two is usually negative even when infection is present. The IDSA, AAN and ACR guideline recommends against testing people who have no symptoms after a bite. If symptoms appear, test then and repeat a few weeks later if the first result is negative.
Is the Western blot more accurate than the ELISA for Lyme disease?
The Western blot is more specific than the ELISA, while the ELISA is more sensitive, so neither is more accurate on its own. The ELISA catches more possible cases but cross-reacts with infections such as Epstein-Barr virus and syphilis. The Western blot confirms that antibodies target Borrelia proteins but misses borderline results. Together, as the two-tier test, they detect roughly 29% to 40% of early Lyme and most late Lyme.
Can you have Lyme disease with a negative test?
Yes, a negative Lyme test does not rule out Lyme disease, especially in the first weeks. Two-tier testing misses roughly 60% to 70% of early localized cases because antibodies have not formed yet. Early antibiotics, immune suppression and less common Borrelia species can also produce false negatives. A clinician may diagnose Lyme from a typical rash and exposure history, or repeat the blood test after a few weeks.
Does a positive Lyme test mean I have an active infection?
A positive two-tier Lyme test shows that you have been exposed to Borrelia burgdorferi, not necessarily that the infection is active now. IgG antibodies can stay positive for months or years after successful treatment, and joint fluid PCR can stay positive for weeks after antibiotics. Your clinician weighs the result against current symptoms, prior treatment and the exam before deciding whether more treatment makes sense.
Who should I see for Lyme disease testing?
A primary care physician or pediatrician can order standard Lyme disease testing and treat most early cases. Infectious disease specialists help with unclear results and late or neurologic Lyme, while rheumatologists and neurologists handle joint and nerve involvement. Integrative and functional medicine clinicians who follow ILADS guidance may order specialty panels. For symptoms that persist after treatment, see the overview of chronic Lyme disease treatment options.
